Congenital Simple Hamartoma of the Retinal Pigment Epithelium (CSHRPE)

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 20 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Congenital Simple Hamartoma of the Retinal Pigment Epithelium (CSHRPE) is a rare, benign ocular lesion characterized by a focal, nodular proliferation of retinal pigment epithelial cells located within the retina itself. Unlike neoplastic tumors, a hamartoma represents a developmental overgrowth of cells normally present at...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Congenital Simple Hamartoma of the Retinal Pigment Epithelium (CSHRPE) is a rare, benign ocular lesion characterized by a focal, nodular proliferation of retinal pigment epithelial cells located within the retina itself. Unlike neoplastic tumors, a hamartoma represents a developmental overgrowth of cells normally present at that site. In CSHRPE, clusters of pigment cells accumulate in a small, well‑circumscribed mass—often near the macula—without true neoplastic transformation....

Key Takeaways

  • This article explains Types in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Symptoms in simple medical language.
  • This article explains Diagnostic Tests in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Sudden vision loss, severe eye pain, new flashes, or many new floaters.
  • Eye symptoms after injury or chemical exposure.
  • Rapidly worsening redness, swelling, or vision changes.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Congenital Simple Hamartoma of the Retinal Pigment Epithelium (CSHRPE) is a rare, benign ocular ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion characterized by a focal, nodular proliferation of retinal pigment epithelial cells located within the retina itself. Unlike neoplastic tumors, a hamartoma represents a developmental overgrowth of cells normally present at that site. In CSHRPE, clusters of pigment cells accumulate in a small, well‑circumscribed mass—often near the macula—without true neoplastic transformation. These lesions are typically deeply pigmented and may appear jet‑black on fundoscopic examination due to their high melanin content PubMed and are restricted entirely to retinal tissue, sometimes protruding toward the vitreous cavity on optical coherence tomography EyeWiki.

Congenital Simple Hamartoma of the Retinal Pigment Epithelium is a noncancerous tumor arising from an overgrowth of normal retinal pigment epithelial cells. Funduscopically, CSHRPE appears as a small (usually <2 mm), sharply demarcated, jet-black nodule located at or near the fovea, often with a sessile or nodule-on-plaque configuration. Optical coherence tomography (OCT) reveals full‑thickness retinal involvement with a hyperreflective mass casting a complete optical shadow on underlying structures, while fluorescein angiography typically shows blocking of fluorescence without intrinsic vascular leakage. Histopathology, when available, confirms a dense proliferation of melanin‑laden RPE cells without atypia or mitotic activity PMCEyeWiki.

Histologically, CSHRPE consists of densely packed pigment epithelial cells without significant atypia or mitotic activity, distinguishing it from adenomas or melanomas of the retinal pigment epithelium. On optical coherence tomography (OCT), these lesions produce a hyperreflective nodular ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion with posterior shadowing and abrupt hyporeflectivity of deeper structures, consistent with dense pigmentation and cellularity EyeWiki. Although congenital in origin, CSHRPE often remains stable throughout life and may be discovered incidentally during routine eye examinations.

Types

While all congenital simple hamartomas of the RPE share common histopathological features, they can be categorized based on location and morphology:

Foveal CSHRPE: These lesions lie within or immediately adjacent to the fovea, the central area responsible for sharp vision. Foveal hamartomas may interfere with central vision, leading to symptomatic visual disturbance if they extend into the foveal pit PubMed.

Extrafoveal CSHRPE: Located outside the foveal zone, these lesions typically spare central vision and are more often detected incidentally due to their asymptomatic nature. Extrafoveal hamartomas may occur in the parafoveal or peripheral retina and usually do not affect visual acuity PubMed.

Morphologically, CSHRPE lesions can also be described as:

  • Nodular and Elevated: A sharply circumscribed, jet‑black nodule projecting toward the vitreous cavity.

  • Sessile and Flat: A less prominent plaque‑like ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion adherent to the inner retinal surface.

These morphological variants reflect differences in how the hamartoma interacts with adjacent retinal layers and can influence the likelihood of tractional complications EyeWiki.

Causes

The precise cause of CSHRPE remains undetermined, and these lesions are thought to arise from developmental anomalies of the retinal pigment epithelium during embryogenesis. Based on embryologic studies of RPE development and analogous focal congenital anomalies, several etiologic factors have been hypothesized:

  1. Developmental Arrest of RPE Progenitor Cells: Embryologically undifferentiated progenitor cells destined for the RPE may fail to receive homeostatic signals for normal differentiation, leading to localized hyperplasia and cell accumulation within the retina PubMed.

  2. Somatic Chromosomal Translocations: Analogous to combined hamartomas, a translocation between chromosome 11 and 18 has been proposed in some focal RPE malformations, possibly disrupting genes that regulate RPE proliferation MedCrave Online.

  3. Somatic Mutations in RPE Growth Genes: Sporadic, non‑inherited mutations affecting key transcription factors such as PAX6 or MITF may alter cell cycle regulation in RPE progenitors.

  4. Epigenetic Dysregulation: Aberrant DNA methylation or histone modification during embryogenesis could misdirect RPE cell fate and proliferation.

  5. Disrupted Wnt Signaling: The Wnt pathway is critical for ocular development; localized defects may result in focal RPE overgrowth.

  6. Abnormal Notch Pathway Activity: Notch signaling influences retinal cell differentiation; its imbalance could favor hamartomatous proliferation.

  7. Growth Factor Imbalance: Excessive local TGF‑β or VEGF during retinal morphogenesis may drive RPE cell hyperplasia.

  8. Intrauterine Hypoxia: Transient low oxygen supply in utero may trigger compensatory cell proliferation in RPE regions.

  9. Maternal Viral Infections: TORCH agents (e.g., rubella, CMV) have been implicated in other congenital retinal lesions; focal viral insult may contribute.

  10. Retinoic Acid Toxicity: Excess maternal vitamin A derivatives can disrupt normal ocular tissue differentiation.

  11. Maternal insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।" data-rx-term="diabetes" data-rx-definition="Diabetes is a condition where blood sugar stays too high because insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।">Diabetes‑Related Oxidative Stress: High glucose levels and free radicals may alter embryonic RPE development.

  12. Placental Insufficiency: Reduced nutrient exchange might lead to localized developmental adaptations in the retina.

  13. Environmental Toxins: Maternal exposure to cigarette smoke or pollutants could produce focal retinal dysgenesis.

  14. Nutritional Deficiencies: Insufficient vitamins (e.g., E or C) during gestation can impair normal RPE cell maturation.

  15. Subclinical Intrauterine infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">Inflammation: Low‑grade inflammatory insults may create micro‑environments favoring RPE overgrowth.

Note: Most of these factors remain theoretical and require further study, as no definitive, population‑based data confirm specific causes of CSHRPE Turkish Journal of OphthalmologyMedCrave Online.

Symptoms

  1. Asymptomatic Presentation: Many individuals have no visual complaints, and CSHRPE is discovered incidentally during routine exams PMC.

  2. Mild Reduction in Visual Acuity: When lesions encroach on the fovea, a slight decrease in sharpness of vision may occur, though acuity often remains near normal PubMed.

  3. Metamorphopsia: Distorted or wavy vision can arise from vitreomacular traction exerted by the hamartoma on adjacent retina EyeWiki.

  4. Central Scotoma: A small, localized blind spot in the center of vision may develop if the ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion directly involves the foveola PubMed.

  5. Floaters: Pigmented cells shed from the ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion into the vitreous can appear as dark spots or “floaters” moving across the visual field PubMed.

  6. Photopsia: Flashes of light may be perceived when the hamartoma causes traction on the inner retinal surface Turkish Journal of Ophthalmology.

  7. Distorted Reading Vision: Epiretinal membrane formation over the ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion can warp the macular contour, making straight lines appear bent during reading EyeWiki.

  8. Blurring from Macular Edema: Secondary swelling of retinal layers adjacent to the hamartoma may further degrade image clarity EyeWiki.

  9. Difficulty with Fine Detail: Tasks like threading a needle can become challenging if the lesion disrupts foveal integrity PubMed.

  10. Peripheral Field Disturbance: Rarely, larger extrafoveal lesions may produce a subtle scotoma in the peripheral field Turkish Journal of Ophthalmology.

Diagnostic Tests

Physical Examination

  1. Visual Acuity Assessment (Snellen Chart): Measures the patient’s clarity of vision at various distances. CSHRPE often spares acuity unless the fovea is involved, yielding near‑normal scores until traction or edema develops EyeWiki.

  2. Pupillary Light Reflex Examination: Evaluates the responsiveness of the pupil to light; normal in CSHRPE but helps rule out afferent pathway lesions Turkish Journal of Ophthalmology.

  3. Intraocular Pressure Measurement (Tonometry): Ensures that intraocular pressure is within normal limits to exclude secondary glaucoma from extensive traction or inflammation Turkish Journal of Ophthalmology.

  4. Slit‑Lamp Biomicroscopy: Allows high‑magnification inspection of the anterior and posterior segments; with a condensing lens, the lesion’s elevation, pigmentation, and surface features can be observed Turkish Journal of Ophthalmology.

Manual Tests

  1. Amsler Grid Evaluation: A simple chart of horizontal and vertical lines used to detect metamorphopsia; distortion of the grid lines suggests macular involvement by the hamartoma EyeWiki.

  2. Ishihara Color Vision Testing: Assesses color discrimination; generally normal in CSHRPE but performed to exclude coexisting optic nerve or inner retinal pathology Turkish Journal of Ophthalmology.

  3. Confrontation Visual Field Testing: A quick screening for gross field defects; small central scotomas from foveal hamartomas may be detected by careful confrontation Turkish Journal of Ophthalmology.

  4. Direct Ophthalmoscopy: Using a handheld scope, the examiner views the fundus through an undilated pupil to confirm the presence of a sharply demarcated, pigmented lesion Turkish Journal of Ophthalmology.

Lab and Pathological Tests

  1. Fine‑Needle Aspiration Cytology (FNAC): Occasionally used when malignancy must be excluded; yields cellular material for cytologic examination, though biopsy is rarely performed due to the benign nature of CSHRPE Turkish Journal of Ophthalmology.

  2. Excisional Biopsy with Histopathology: In surgical cases, the lesion can be removed and examined microscopically, confirming a benign proliferation of RPE cells without atypia or mitoses EyeWiki.

  3. Immunohistochemical Staining: Uses antibodies against cytokeratin and melanocyte markers (e.g., melan A) to demonstrate RPE origin and distinguish from melanoma or adenoma EyeWiki.

Electrodiagnostic Tests

  1. Full‑Field Electroretinography (ffERG): Records global retinal electrical responses to light stimuli; typically normal in focal hamartomas, helping differentiate localized lesions from diffuse retinal disorders Turkish Journal of Ophthalmology.

  2. Multifocal Electroretinography (mfERG): Maps localized retinal function, revealing reduced responses in the area of the hamartoma, thereby confirming focal functional impairment EyeWiki.

  3. Electrooculography (EOG): Assesses RPE function by measuring standing potentials; may show subtle alterations if the lesion affects RPE integrity over a broad area Turkish Journal of Ophthalmology.

Imaging Tests

  1. Optical Coherence Tomography (OCT): Produces high‑resolution cross‑sectional images of the retina, demonstrating a hyperreflective nodular lesion protruding toward the vitreous with posterior shadowing and sharp margins EyeWiki.

  2. OCT Angiography (OCTA): Visualizes blood flow within retinal capillary plexuses; may show vascular patterns around the hamartoma without true intrinsic neovascularization EyeWiki.

  3. Fundus Photography: Color images document the jet‑black appearance, size, and location of the lesion, providing a baseline for monitoring any changes over time EyeWiki.

  4. Fundus Autofluorescence (FAF): Highlights areas of lipofuscin accumulation; CSHRPE appears hypoautofluorescent due to dense melanin absorption EyeWiki.

  5. Fluorescein Angiography (FA): Reveals blockage of background choroidal fluorescence at the lesion site, with possible late ring‑form hyperfluorescence due to staining of adjacent retina EyeWiki.

  6. B‑Scan Ultrasonography: Shows an elevated, echogenic mass with acoustic shadowing, helping to distinguish a hamartoma from a flat choroidal nevus or melanoma Turkish Journal of Ophthalmology.

Non‑Pharmacological Treatments

While CSHRPE itself rarely requires intervention, supportive measures may help maintain overall eye health and patient comfort. These strategies fall into three categories: Exercise Therapies, Mind‑Body Techniques, and Educational Self‑Management.

Exercise Therapies

  1. Vision Therapy
    Description: Supervised in‑office and at‑home ocular exercises designed to enhance visual skills through neuroplasticity.
    Purpose: To maintain ocular motility and binocular coordination, potentially reducing strain around focal lesions.
    Mechanism: Repeated vergence and saccadic tasks stimulate neural pathways involved in eye movement control Cleveland Clinic.

  2. Accommodation Training
    Description: Near‑far focusing drills using accommodative lenses or print cards.
    Purpose: To sustain lens flexibility and reduce accommodative fatigue that may arise with focal retinal lesions.
    Mechanism: Alters ciliary muscle activity and lens shape, promoting efficient focus adjustments Aetna.

  3. Saccadic Jump Exercises
    Description: Rapid eye‑movement tasks between two targets.
    Purpose: To improve eye‑movement accuracy and reduce compensatory head movements.
    Mechanism: Trains extraocular muscles and associated neural circuits for precise gaze shifts PMC.

  4. Pursuit Tracking
    Description: Smooth following of moving objects under supervision.
    Purpose: To sustain smooth pursuit function, minimizing strain near the lesion.
    Mechanism: Engages cortical and cerebellar pathways governing continuous eye movements CareCredit.

  5. Fusional Vergence Therapy
    Description: Prism‑based convergence and divergence exercises with stereograms.
    Purpose: To reinforce binocular alignment and comfort, especially when lesions lie near the macula.
    Mechanism: Stimulates fusional vergence centers in the brainstem AAPOS.

  6. Blink‑and‑Relax Sequences
    Description: Scheduled blinking and relaxation to maintain tear film and reduce ocular surface dryness.
    Purpose: To enhance comfort during prolonged near work.
    Mechanism: Preserves corneal hydration and prevents reflex strain midtownoptometry.com.

  7. Eye‑Hand Coordination Drills
    Description: Catch‑and‑throw or touchscreen tracking games.
    Purpose: To keep neural visual‑motor integration active.
    Mechanism: Synchronizes visual input with motor output for overall visual function applevalleyvision.com.

Mind‑Body Techniques

  1. Yoga and Transcendental Meditation
    Description: Gentle postures combined with mantra‑based meditation.
    Purpose: To reduce stress and support retinal microcirculation.
    Mechanism: Enhances retinal blood flow via vasodilation and reduced sympathetic tone MDPI.

  2. Mindfulness‑Based Stress Reduction (MBSR)
    Description: Structured meditation program focusing on breath and body awareness.
    Purpose: To lower intraocular pressure and improve optic nerve perfusion.
    Mechanism: Diminishes cortisol‑mediated vascular constriction, stabilizing ocular hemodynamics ScienceDirect.

  3. Progressive Muscle Relaxation
    Description: Systematic tensing and relaxing of muscle groups, including periorbital muscles.
    Purpose: To alleviate periocular tension and associated discomfort.
    Mechanism: Reduces local muscle tone, enhancing circulation around the eye PubMed.

  4. Guided Imagery for Visual Comfort
    Description: Scripted visualizations of soothing environments.
    Purpose: To distract from ocular awareness and reduce perceived strain.
    Mechanism: Activates parasympathetic pathways, decreasing sympathetic‑driven ocular stress phxeyedoctor.

  5. Biofeedback‑Assisted Relaxation
    Description: Real‑time physiological monitoring (e.g., heart rate) with relaxation training.
    Purpose: To teach control over stress responses that may influence ocular perfusion.
    Mechanism: Trains autonomic balance, favoring ocular blood flow stability The Open Ophthalmology Journal.

  6. Acupuncture Around Periocular Points
    Description: Insertion of fine needles near specific acupoints.
    Purpose: To improve microcirculation and reduce periocular tension.
    Mechanism: May trigger local neurovascular responses enhancing retinal nourishment PMC.

  7. Deep‑Breathing Exercises
    Description: Diaphragmatic breathing routines lasting several minutes.
    Purpose: To decrease intraocular pressure fluctuations.
    Mechanism: Modulates autonomic tone and intra‑thoracic pressure impacting ocular perfusion ScienceDirect.

Educational Self‑Management

  1. Daily Amsler Grid Testing
    Description: Home use of a printed Amsler grid to self‑monitor central vision.
    Purpose: Early detection of metamorphopsia or scotoma indicating lesion change.
    Mechanism: Patients focus on center dot and note any line distortions, calling their doctor if changes occur Cleveland ClinicNCBI.

  2. Vision Diary
    Description: Daily log of visual symptoms, activities that trigger strain, and environmental factors.
    Purpose: To track subtle changes prompting timely ophthalmic evaluation.
    Mechanism: Empowers patients to recognize patterns and communicate effectively with clinicians.

  3. Smartphone App Reminders
    Description: Use of health apps to schedule and log eye‑care tasks (e.g., grid tests, appointments).
    Purpose: To enhance adherence to follow‑up schedules.
    Mechanism: Automated notifications improve compliance and early detection of changes.

  4. Nutrition and Hydration Logs
    Description: Recording daily intake of ocular‑beneficial foods and fluids.
    Purpose: To reinforce diet patterns supporting retinal health.
    Mechanism: Encourages intake of antioxidants and hydration, aiding retinal cell function National Eye Institute.

  5. Online Patient Education Modules
    Description: Structured courses from reputable sources (e.g., AAO EyeSmart).
    Purpose: To improve understanding of CSHRPE and associated eye‑care strategies.
    Mechanism: Multimedia content enhances retention and self‑efficacy Review of Ophthalmology.

  6. Support Group Participation
    Description: Engagement with patient communities for shared experiences.
    Purpose: To reduce anxiety and gain practical management tips.
    Mechanism: Peer learning fosters proactive self‑management and emotional support.

Drugs

CSHRPE itself generally does not respond to medications, but drugs may be used to manage rare complications such as neovascularization or macular edema. The following are off‑label or symptomatic treatments:

  1. Bevacizumab (Avastin)
    Dosage: Intravitreal 1.25 mg in 0.05 mL every 4–6 weeks as needed.
    Class: Anti‑VEGF monoclonal antibody.
    Timing: Monthly injections initially, then PRN.
    Side Effects: Endophthalmitis, transient IOP elevation, intraocular hemorrhage EyeWiki.

  2. Ranibizumab (Lucentis)
    Dosage: Intravitreal 0.5 mg monthly.
    Class: Anti‑VEGF antibody fragment.
    Timing: Monthly maintenance.
    Side Effects: Similar to bevacizumab, including injection‑related complications PMC.

  3. Aflibercept (Eylea)
    Dosage: Intravitreal 2 mg every 4 weeks for 5 doses, then every 8 weeks.
    Class: VEGF‑trap fusion protein.
    Timing: Monthly then bimonthly.
    Side Effects: Endophthalmitis, IOP spikes Aetna.

  4. Triamcinolone Acetonide
    Dosage: Intravitreal 4 mg injection once every 3–4 months.
    Class: Corticosteroid.
    Timing: Quarterly.
    Side Effects: Cataract progression, glaucoma PMC.

  5. Dexamethasone Intravitreal Implant (Ozurdex)
    Dosage: 0.7 mg implant every 4–6 months.
    Class: Sustained‑release corticosteroid.
    Timing: As indicated by edema recurrence.
    Side Effects: Elevated IOP, cataract formation Aetna.

  6. Acetazolamide (Diamox)
    Dosage: 500 mg orally twice daily.
    Class: Carbonic anhydrase inhibitor.
    Timing: Daily.
    Side Effects: Paresthesia, metabolic acidosis, hypokalemia MedscapeWikipedia.

  7. Topical Nonsteroidal Anti‑Inflammatory Drugs (NSAIDs)
    Dosage: Ketorolac tromethamine 0.5% drops four times daily.
    Class: NSAID.
    Timing: During inflammatory episodes.
    Side Effects: Ocular irritation, corneal thinning.

  8. Povidone‑Iodine Pre‑Injection
    Dosage: 5% ocular prep before intravitreal injection.
    Class: Antiseptic.
    Timing: Single application prior to injection.
    Side Effects: Temporary stinging Wikipedia.

  9. Oral Steroids (Prednisone)
    Dosage: 40 mg daily taper.
    Class: Systemic corticosteroid.
    Timing: Short course for severe inflammatory complications.
    Side Effects: Systemic side effects including hyperglycemia.

  10. Prophylactic Antibiotic Drops
    Dosage: Moxifloxacin 0.5% one drop pre‑ and post‑injection.
    Class: Fluoroquinolone antibiotic.
    Timing: Before and after intravitreal procedure.
    Side Effects: Ocular surface irritation.

Dietary Molecular Supplements

Though not specific to CSHRPE, the following supplements support retinal health:

  1. Lutein (10 mg/day)
    Function: Macular pigment density.
    Mechanism: Filters blue light, antioxidant National Eye Institute.

  2. Zeaxanthin (2 mg/day)
    Function: Central macular protection.
    Mechanism: Blue-light absorption, free‑radical scavenging National Eye Institute.

  3. Omega‑3 Fatty Acids (DHA 350 mg, EPA 650 mg)
    Function: Neural retina membrane integrity.
    Mechanism: Anti‑inflammatory, enhances photoreceptor function National Eye Institute.

  4. Vitamin C (500 mg/day)
    Function: Collagen synthesis support.
    Mechanism: Water‑soluble antioxidant JAMA Network.

  5. Vitamin E (400 IU/day)
    Function: Lipid membrane protection.
    Mechanism: Lipid‑soluble antioxidant JAMA Network.

  6. Zinc (80 mg/day)
    Function: Retinal pigment metabolism.
    Mechanism: Cofactor in superoxide dismutase PMC.

  7. Copper (2 mg/day)
    Function: Prevent zinc‑induced deficiency.
    Mechanism: Essential trace element synergy JAMA Network.

  8. Vitamin A (as beta‑carotene 15 mg/day)
    Function: Photoreceptor function.
    Mechanism: Retinaldehyde precursor American Optometric Association.

  9. Bilberry Extract (160 mg twice daily)
    Function: Microvascular support.
    Mechanism: Anthocyanin antioxidants Verywell Health.

  10. Ginkgo Biloba (120 mg/day)
    Function: Microcirculation enhancement.
    Mechanism: Vasoactive and antioxidant effects.

Regenerative and Stem Cell Drugs

No regenerative or stem cell therapies are currently approved specifically for CSHRPE. Investigational approaches for RPE restoration include:

  1. hESC‑RPE Cell Suspension
    Dosage: 150,000–200,000 cells subretinally.
    Function: Replace damaged RPE.
    Mechanism: Integrates into Bruch’s membrane and phagocytoses photoreceptor outer segments.

  2. iPSC‑Derived RPE Sheets
    Dosage: One sheet (~1 mm²).
    Function: Structural RPE restoration.
    Mechanism: Reestablishes RPE monolayer, supports photoreceptors.

  3. RPE Transplant Bruch Membrane Scaffold
    Dosage: Scaffold seeded with 200k cells.
    Function: Sustained RPE support.
    Mechanism: Biomatrix promotes cell adhesion and survival.

  4. Gene‑Therapy Vectors (AAV‑RPE65)
    Dosage: 1 × 10¹¹ vector genomes.
    Function: Correct RPE dysfunction.
    Mechanism: Delivers healthy RPE65 gene to improve visual cycle.

  5. Mesenchymal Stem Cell Paracrine Therapy
    Dosage: 1 × 10⁶ cells intravitreal.
    Function: Neuroprotection.
    Mechanism: Secretes trophic factors supporting retinal neurons.

  6. Exosome‑Based RPE Support
    Dosage: 10 µg exosomal protein intravitreal.
    Function: Anti‑inflammatory and regenerative signaling.
    Mechanism: Transfers miRNAs regulating cell survival pathways.

Surgeries

  1. Pars Plana Vitrectomy with Tumor Excision
    Procedure: Removal of vitreous humor and surgical resection of the hamartoma.
    Benefits: Histopathology confirmation, relief of traction if epiretinal membrane present PMC.

  2. Focal Argon Laser Photocoagulation
    Procedure: Targeted laser spots around lesion edges.
    Benefits: Stabilizes vascular lesions, prevents exudation PMC.

  3. Cryotherapy
    Procedure: Transscleral freezing of lesion.
    Benefits: Induces localized tissue regression with minimal collateral damage.

  4. Photodynamic Therapy (PDT)
    Procedure: Intravenous photosensitizer (verteporfin) followed by laser activation.
    Benefits: Vascular occlusion of neovascular membranes, minimal damage to adjacent retina.

  5. Epiretinal Membrane Peeling
    Procedure: Removal of secondary epiretinal membrane via vitrectomy.
    Benefits: Improves visual acuity and relieves traction PMC.

Preventions

  1. MMR Vaccination Before Pregnancy
    Ensures rubella immunity, preventing CRS and associated ocular anomalies CDCWikipedia.

  2. Avoiding Maternal Rubella Infection
    Daily monitoring and isolation post‑exposure during pregnancy reduces risk CDC.

  3. Periconceptional Folic Acid (400 µg/day)
    Lowers risk of neural‑tube and ocular congenital malformations PMCFrontiers.

  4. Avoidance of Teratogens
    Strict abstinence from alcohol, thalidomide, and retinoic acid during pregnancy prevents ocular maldevelopment.

  5. Control of Maternal Diabetes
    Maintains normoglycemia to reduce congenital anomaly risk.

  6. Smoking Cessation
    Eliminates oxidative stress to developing fetal tissues.

  7. Radiation Avoidance
    Minimizes fetal exposure to ionizing radiation during organogenesis.

  8. Prenatal Genetic Counseling
    Identifies familial risks and guides reproductive choices.

  9. Adequate Maternal Nutrition
    Balanced diet rich in vitamins C, E, zinc, omega‑3 supports embryonic eye development.

  10. Regular Prenatal Ultrasound
    Early detection of ocular or systemic anomalies to plan perinatal care.

When to See a Doctor

Seek prompt ophthalmic evaluation if you notice:

  • New or worsening metamorphopsia, distortions on the Amsler grid.

  • Sudden changes in visual acuity or color perception.

  • Floaters, flashes of light, or a curtain‑like shadow.

  • Persistent eye pain or redness after interventions.

  • Any unexpected visual changes that last more than 24 hours Cleveland ClinicHealthline.

What to Do and What to Avoid

What to Do:

  • Perform daily Amsler grid self‑tests.

  • Attend scheduled ophthalmology follow‑ups.

  • Wear UV‑blocking sunglasses outdoors Prevent BlindnessAmerican Academy of Ophthalmology.

  • Maintain a nutrient‑rich diet and stay hydrated Verywell Health.

  • Use prescribed lubricating drops during prolonged near work.

  • Log visual symptoms and triggers.

  • Practice stress‑reduction techniques.

  • Monitor systemic health (blood pressure, glucose).

  • Follow post‑injection care instructions.

  • Report any infection signs after ocular procedures.

What to Avoid:

  • Rubbing or pressing on eyes.

  • Unprotected UV exposure without sunglasses.

  • Smoking or exposure to secondhand smoke.

  • Skipping follow‑up appointments.

  • Excessive screen time without breaks (“20‑20‑20” rule).

  • Unsupervised use of supplements beyond recommended doses.

  • Overuse of topical NSAIDs.

  • Head‑down positions if advised against by your physician.

  • Ignoring minor visual changes.

  • Using non‑sterile eye products.

Frequently Asked Questions

  1. What is CSHRPE?
    CSHRPE is a rare, benign overgrowth of retinal pigment epithelial cells forming a small, pigmented nodule near the macula. It is typically stable and discovered by chance during eye exams PMC.

  2. How does CSHRPE differ from CHRPE?
    While CHRPE lesions are flat, hyperpigmented patches often linked with familial polyposis syndromes, CSHRPE is a nodular, full‑thickness mass of RPE cells unassociated with systemic disease NCBI.

  3. What causes CSHRPE?
    Its exact cause is unknown, but it results from developmental anomalies of RPE cells during embryogenesis, leading to localized cell hyperplasia.

  4. How is CSHRPE diagnosed?
    Diagnosis relies on fundus examination, OCT revealing a hyperreflective full‑thickness lesion, and fluorescein angiography showing blockage without leakage EyeWiki.

  5. What symptoms does it cause?
    Most patients are asymptomatic; rare cases may experience mild visual distortion if lesions impinge on the fovea.

  6. Is CSHRPE cancerous?
    No, it is a benign hamartoma without malignant potential.

  7. Can it affect my vision long‑term?
    Lesions are usually stable with minimal impact; regular monitoring ensures any changes are detected early.

  8. Are there treatments?
    No direct treatments for the lesion itself; management focuses on monitoring and addressing complications such as edema.

  9. When is surgery needed?
    Surgical excision via pars plana vitrectomy is reserved for symptomatic cases with epiretinal membrane or vision‑threatening complications PMC.

  10. Can CSHRPE grow over time?
    Rare reports describe slow growth; most remain unchanged over years JAMA Network.

  11. Should my children be screened?
    Routine pediatric eye exams suffice, as inheritance is not established; family screening is not routinely indicated.

  12. Is it inherited?
    No clear genetic pattern; CSHRPE is considered a sporadic congenital anomaly.

  13. What complications can arise?
    Rare complications include macular edema or epiretinal membrane formation requiring intervention.

  14. How often should I have eye exams?
    Annual dilated exams are recommended to ensure lesion stability.

  15. Where can I learn more?
    Trusted resources include PubMed case reports, AAO EyeSmart, and peer‑reviewed ophthalmology literature.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 19, 2025.

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Doctor / qualified healthcare provider
Tests to discuss with doctor
  • Basic vital signs: temperature, pulse, blood pressure, oxygen level if needed
  • Relevant blood, urine, imaging, or specialist tests only after clinical assessment
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Congenital Simple Hamartoma of the Retinal Pigment Epithelium (CSHRPE)

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Congenital Iris Ectropion

    DefinitionCongenital? iris ectropion is more commonly called congenital? ectropion uveae. It is a rare developmental eye condition present from birth in which the dark pigment layer...

    April 2, 2026 • Rx Eye & Vision Care (A - Z)
  2. Congenital Cystic Eyeball

    DefinitionCongenital? cystic eyeball, also called congenital? cystic eye, is a very rare birth defect in which a cyst forms in the eye socket and the normal...

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  3. Congenital Anophthalmos with Cyst

    DefinitionCongenital? anophthalmos with cyst is a very rare birth defect of eye development. In this condition, a child is born without a normally formed eye in...

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  4. Congenital Cystic Eye

    DefinitionCongenital? cystic eye is a very rare birth condition. In this condition, a cyst-like sac grows in the eye socket where the eye should normally form....

    March 31, 2026 • Rx Eye & Vision Care (A - Z)
  5. Cerulean Cataract

    DefinitionCerulean cataract is a rare kind of childhood or developmental cataract. A cataract means the natural lens of the eye becomes cloudy instead of staying clear....

    March 12, 2026 • Rx Eye & Vision Care (A - Z)
  6. Congenital Blue Dot Cataract

    DefinitionCongenital? blue dot cataract, also called cerulean cataract, is a type of childhood lens opacity in which many tiny bluish or whitish dots appear in the...

    March 12, 2026 • Rx Eye & Vision Care (A - Z)
  7. Congenital Achiasma

    DefinitionCongenital? achiasma is a very rare eye and brain problem that is present from birth. It happens when the optic chiasm, the “cross-road” where nerve fibers...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  8. Congenital Absence of Lacrimal Puncta and Salivary Glands

    DefinitionCongenital? absence of lacrimal puncta and salivary glands means that a baby is born without the tiny tear drainage openings on the eyelids (lacrimal puncta) and...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  9. Aplasia of the Lacrimal and Salivary Glands

    DefinitionAplasia of the lacrimal and salivary glands means that the tear glands and saliva glands did not grow properly before birth. They are partly formed, very...

    March 5, 2026 • Rx Eye & Vision Care (A - Z)
  10. Cone-Rod Dystrophy Type 6

    DefinitionCone-rod dystrophy type 6 (often written as CORD6) is a rare eye disease that slowly damages the light-sensing cells (cones and rods) in the retina, the...

    March 4, 2026 • Rx Eye & Vision Care (A - Z)